Stay updated with breaking news from Gabapentin Tablets. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Zydus Lifesciences announced that it has obtained approval from the USFDA to sell a generic medication for the treatment of postherpetic neuralgia. The company has received the final nod from the US Food and Drug Administration (USFDA) to produce and distribute Gabapentin tablets in strengths of 300 mg and 600 mg, as stated in a regulatory filing by Zydus Lifesciences.
India News: Zydus Lifesciences has received approval from the US Food and Drug Administration (USFDA) to market a generic medication to manage postherpetic neuralgia. Read more.
Press Release For Immediate Release Granules India Limited Received ANDA Approval for Gabapentin Tablets ... | March 29, 2023
Zydus Lifesciences Limited’s subsidiary, Zydus Pharmaceuticals (USA) Inc., has received tentative approval from the United States Food and Drug Administration (USFDA) for Gabapentin Tablets, the company said via an exchange filing. The recommended daily dose is 300 mg or 600 mg (Gralise Tablets). Gabapentin tablets are indicated for the management of Postherpetic Neuralgia (PHN).
Zydus Lifesciences Ltd's subsidiary Zydus Pharmaceuticals USA Inc. has received tentative approval from the United USFDA for Gabapentin Tablets Once-Daily, 300 mg and 600 mg.